LDL Subclasses Ratio Predicts Cardiovascular Disease Risk More Accurately than LDL-cholesterol Alone
|
By LabMedica International staff writers Posted on 27 Nov 2019 |

Image: Small particle LDL has been associated with the progression of atherosclerosis and blockage the artery lumen, because it can carry cholesterol into smaller vessels. As atheroma enlarges, the arterial wall ruptures and releases blood clots that lead to narrowing of the artery (Photo courtesy of Wikimedia Commons)
Measurement of low-density lipoprotein (LDL) cholesterol may a less effective way to predict risk of cardiovascular disease than is the further analysis of the relative proportions of LDL subclasses.
About 75% of patients with heart attacks have cholesterol levels, particularly LDL-cholesterol levels - that do not indicate a high risk for a cardiovascular event. LDL comprises a diverse group of macromolecules that may be grouped according to size: large low density LDL particles are described as subclass A, and small high density LDL particles are subclass B. Subclass B has been associated by some with a higher risk for coronary heart disease. This is thought to be because the smaller particles are more easily able to penetrate the endothelium of arterial walls. Subclass I, for intermediate, indicates that most LDL particles are very close in size to the normal gaps in the endothelium.
A recent study carried out at Ohio University (Athens, USA) suggested that contrary to the current [U.S.] national guidelines it was not the total LDL, rather it was the concentration of subclass B in relation to subclasses A and/or I, that should be used for diagnosis of atherosclerosis and the risk of heart attack.
The investigators reached this conclusion after utilizing a nanomedical approach. They used nanosensors with a diameter of less than 300 nanometers, to simultaneously measure, in near-real time, the concentration of cytoprotective nitric oxide (NO) and cytotoxic peroxynitrite (ONOO−) released from a single endothelial cell exposed to each of the LDL subclasses (A, B, and I). The ratio of NO concentration to ONOO− concentration (NO)/(ONOO−) was used as a marker of oxidative stress and the dysfunction of the enzyme endothelial nitric oxide synthase (eNOS).
Results revealed that all n-LDL (native LDL) and ox-LDL (oxidized LDL) subclasses unfavorably shifted the balance of the (NO)/(ONOO−) ratio, imposing toxic effects such as: elevated oxidative stress, a shortage of cytoprotective NO, and the up-regulation of adhesion molecules in the endothelium. However, subclass B dramatically shifted (NO)/(ONOO−) balance to a very low level, causing significant damage to endothelial function.
"Our studies can explain why a correlation of total "bad" cholesterol with a risk of heart attack is poor and dangerously misleading – it is wrong three quarters of the time," said senior author Dr. Tadeusz Malinski, professor of chemistry and biochemistry at Ohio University. "These national guidelines may seriously underestimate the noxious effects of LDL cholesterol, especially in cases where the content of subclass B in total LDL is high (50% or higher). Understanding this could lead to improving the accuracy of diagnosis for the evaluation of cardiovascular disease rates. Analyzing the mixture of LDL subclasses may provide a parameter-based model for an early medical diagnosis of estimating the risk of cardiovascular disease."
The study was published in the November 18, 2019, issue of the International Journal of Nanomedicine.
Related Links:
Ohio University
About 75% of patients with heart attacks have cholesterol levels, particularly LDL-cholesterol levels - that do not indicate a high risk for a cardiovascular event. LDL comprises a diverse group of macromolecules that may be grouped according to size: large low density LDL particles are described as subclass A, and small high density LDL particles are subclass B. Subclass B has been associated by some with a higher risk for coronary heart disease. This is thought to be because the smaller particles are more easily able to penetrate the endothelium of arterial walls. Subclass I, for intermediate, indicates that most LDL particles are very close in size to the normal gaps in the endothelium.
A recent study carried out at Ohio University (Athens, USA) suggested that contrary to the current [U.S.] national guidelines it was not the total LDL, rather it was the concentration of subclass B in relation to subclasses A and/or I, that should be used for diagnosis of atherosclerosis and the risk of heart attack.
The investigators reached this conclusion after utilizing a nanomedical approach. They used nanosensors with a diameter of less than 300 nanometers, to simultaneously measure, in near-real time, the concentration of cytoprotective nitric oxide (NO) and cytotoxic peroxynitrite (ONOO−) released from a single endothelial cell exposed to each of the LDL subclasses (A, B, and I). The ratio of NO concentration to ONOO− concentration (NO)/(ONOO−) was used as a marker of oxidative stress and the dysfunction of the enzyme endothelial nitric oxide synthase (eNOS).
Results revealed that all n-LDL (native LDL) and ox-LDL (oxidized LDL) subclasses unfavorably shifted the balance of the (NO)/(ONOO−) ratio, imposing toxic effects such as: elevated oxidative stress, a shortage of cytoprotective NO, and the up-regulation of adhesion molecules in the endothelium. However, subclass B dramatically shifted (NO)/(ONOO−) balance to a very low level, causing significant damage to endothelial function.
"Our studies can explain why a correlation of total "bad" cholesterol with a risk of heart attack is poor and dangerously misleading – it is wrong three quarters of the time," said senior author Dr. Tadeusz Malinski, professor of chemistry and biochemistry at Ohio University. "These national guidelines may seriously underestimate the noxious effects of LDL cholesterol, especially in cases where the content of subclass B in total LDL is high (50% or higher). Understanding this could lead to improving the accuracy of diagnosis for the evaluation of cardiovascular disease rates. Analyzing the mixture of LDL subclasses may provide a parameter-based model for an early medical diagnosis of estimating the risk of cardiovascular disease."
The study was published in the November 18, 2019, issue of the International Journal of Nanomedicine.
Related Links:
Ohio University
Latest Molecular Diagnostics News
- Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
- Portable Rapid Test Aims to Detect Ebola at Point of Care
- New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
- Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
- Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
- Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
- New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
- Blood-Based Gene Expression Test Detects Early Pancreatic Cancer
- Blood-Based Biomarker Panel Outperforms Existing Liver Disease Tests
- Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
- HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
- Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
- Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
- Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations
- Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
- Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Channels
Clinical Chemistry
view channel
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read more
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
NanoSomiX, Inc. and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs).... Read more








